A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

NCT03880019 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

NIH

Sponsor class

Conditions

Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
Uterine Corpus Leiomyosarcoma

Interventions

PROCEDURE: Computed Tomography
PROCEDURE: Core Biopsy
PROCEDURE: Magnetic Resonance Imaging
DRUG: Olaparib
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)